Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies

Miguel Quijada-Álamo; Grace Freed; Elvin Wagenblast

doi:10.1158/2643-3230.BCD-25-0036

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies

Miguel Quijada-Álamo
, Grace Freed
, Elvin Wagenblast

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Summary: Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.

Original language	English
Pages (from-to)	293-297
Number of pages	5
Journal	Blood cancer discovery
Volume	6
Issue number	4
DOIs	https://doi.org/10.1158/2643-3230.BCD-25-0036
State	Published - 1 Jul 2025

Access to Document

10.1158/2643-3230.BCD-25-0036

Cite this

@article{54ee0d90d61c4019819f8f4044e64f50,

title = "Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies",

abstract = "Summary: Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.",

author = "Miguel Quijada-{\'A}lamo and Grace Freed and Elvin Wagenblast",

note = "Publisher Copyright: {\textcopyright}2025 American Association for Cancer Research.",

year = "2025",

month = jul,

day = "1",

doi = "10.1158/2643-3230.BCD-25-0036",

language = "English",

volume = "6",

pages = "293--297",

journal = "Blood cancer discovery",

issn = "2643-3230",

publisher = "American Association for Cancer Research Inc.",

number = "4",

}

TY - JOUR

T1 - Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies

AU - Quijada-Álamo, Miguel

AU - Freed, Grace

AU - Wagenblast, Elvin

PY - 2025/7/1

Y1 - 2025/7/1

N2 - Summary: Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.

AB - Summary: Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.

UR - https://www.scopus.com/pages/publications/105010203152

U2 - 10.1158/2643-3230.BCD-25-0036

DO - 10.1158/2643-3230.BCD-25-0036

M3 - Review article

C2 - 40287957

AN - SCOPUS:105010203152

SN - 2643-3230

VL - 6

SP - 293

EP - 297

JO - Blood cancer discovery

JF - Blood cancer discovery

IS - 4

ER -

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies

Abstract

Access to Document

Fingerprint

Cite this